- Home
- AVPT vs VRDN Comparison
AVPT vs VRDN Comparison
Compare AVPT & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVPT | VRDN |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | 3443 | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | AVPT | VRDN |
|---|---|---|
| Price | $13.43 | $22.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $16.64 | ★ $35.46 |
| AVG Volume (30 Days) | ★ 1.6M | 1.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $25.00 | $13.73 |
| Revenue Next Year | $19.63 | $279.00 |
| P/E Ratio | $1,348.94 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.84 | $13.18 |
| 52 Week High | $16.77 | $34.29 |
Technical Indicators
Market Signals| Indicator | AVPT | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 54.88 | 53.47 |
| Support Level | $12.92 | $21.62 |
| Resistance Level | $13.71 | $24.86 |
| Average True Range (ATR) | 0.41 | 0.80 |
| MACD | -0.03 | -0.29 |
| Stochastic Oscillator | 49.84 | 32.46 |
Price Performance
Historical ComparisonAbout AVPT AvePoint Inc.
AvePoint Inc is a provider of modern data protection, enabling organizations to secure, govern, and operationalize data at scale across cloud ecosystems. Customers rely on the AvePoint Confidence Platform to reduce risk, improve operational efficiency, and accelerate digital transformation as it adopt cloud collaboration and artificial intelligence (AI)-driven developed tools and workflows. Its products and services are sold throughout the world, through direct and indirect sales channels.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.